Science Daily -
7 Jan 2014 20:59
No positive effects regarding mortality, symptoms and quality of life can be derived from the available data on the use of Dabrafenib in melanoma treatment. The side effects are too concerning, says a new study, and overall, the data are too uncertain for it to be recommended.
Share this Article